Recruiting
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
NCT05176483
- Conditions
- Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +47 more
- Locations
-
- Exelixis Clinical Site #67 Phoenix, Arizona, United States
- Exelixis Clinical Site #1 Tucson, Arizona, United States
- Exelixis Clinical Site #123 Palo Alto, California, United States
- Exelixis Clinical Site #59 Santa Barbara, California, United States